Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug boost heart ablation success?

NCT ID NCT07389941

Disease control Sponsor: University of Luebeck Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking semaglutide (a drug used for diabetes and weight loss) before a standard heart procedure called catheter ablation can help prevent atrial fibrillation from coming back. The trial will include 240 adults with obesity and symptomatic atrial fibrillation who are having their first ablation. Participants will receive either semaglutide plus ablation or standard care alone, and researchers will check heart rhythm after 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Semaglutide (a drug for weight and diabetes management)
What this could lead to
If it works, this could show that pre-treatment with semaglutide helps prevent atrial fibrillation from returning after ablation in people with obesity.
What could go wrong
This is a Phase 4 trial, but it's not yet recruiting and has a moderate size (240 participants). The benefit may be small or not apply to all patients, and semaglutide can cause side effects like nausea or gastrointestinal issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Age 18-80 years * Symptomatic paroxysmal or persistent AF eligible for first-time catheter ablation * Body mass index ≥30 kg/m or body mass index ≥28 kg/m plus ≥1 weight-related comorbidity * No prior treatment with glucacon-like peptide-1 receptor agonists Exclusion criteria: * Current use of glucacon-like peptide-1 receptor agonists or dipeptidyl peptidase 4 inhibitors or use within the last 90 days prior to screening * Current antiobesity medication use or use within the last 90 days prior to screening * A self-reported change in body weight of \>5 kg within 30 days before screening * History of bariatric surgery * History of diabetes mellitus * Hospitalization for unstable angina, or transient ischemic attack \<30 days prior to screening * Pulmonary embolism \<90 days before screening * Myocardial infarction, or stroke \<90 days prior to screening * Uncontrolled thyroid disease: thyroid-stimulating hormone \>10.0 mIU/L or \<0.4 mIU/L at screening * Active malignancy * Acute pancreatitis \<180 days before screening * History or presence of chronic pancreatitis * Chronic kidney disease with creatinine clearance \<30 mL/min * Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 * Chronic inflammatory conditions requiring immunosuppression and/or on glucocorticoids * Pregnancy, breast-feeding or planning pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.